Significance of CD66c expression in childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 42-48

  Kiyokawa, Nobutaka ^a   Iijima, Kazutoshi ^a   Tomita, Osamu ^a   Miharu, Masashi ^a,b   Hasegawa, Daisuke ^a,c   Kobayashi, Kenichiro ^a   Okita, Hajime ^a   Kajiwara, Michiko ^d   Shimada, Hiroyuki ^b   Inukai, Takeshi ^e   Makimoto, Atsushi ^f   Fukushima, Takashi ^g   Nanmoku, Toru ^h   Koh, Katsuyoshi ⁱ   Manabe, Atsushi ^c   Kikuchi, Akira ^j   Sugita, Kanji ^e   Fujimoto, Junichiro ^k   Hayashi, Yasuhide ^l   Ohara, Akira ^m  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

ⁱ SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^j TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^l Gumna Children S Medical Center   (Japan)

^m TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

more..

Author keywords

Acute lymphoblastic leukemia; CD66c; CRLF2, Flow cytometry; Genetic abnormality

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD15 ANTIGEN; CD33 ANTIGEN; LYMPHOCYTE ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME NUMBER; DIPLOIDY; E2A PBX1 GENE; ETV6 RUNX1 GENE; GENE; GENE EXPRESSION; GENETIC DISORDER; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MLL AF4 GENE; MLL AF9 GENE; MLL ENL GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD;

EID: 84890547704     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.008     Document Type: Article

References (34)

1. Greaves M.F., Chan L.C., Furley A.J., Watt S.M., Molgaard H.V. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 1986, 67:1-11.
2. Schmidt C.A., Przybylski G.K. What can we learn from leukemia as for the process of lineage commitment in hematopoiesis?. Int Rev Immunol 2001, 20:107-115.
3. Béné M.C., Porwit A. Acute leukemias of ambiguous lineage. Semin Diagn Pathol 2012, 29:12-18.
4. Sugita K., Mori T., Yokota S., Kuroki M.a., O-Koyama T., Inukai T., et al. The KOR-SA3544 antigen predominantly expressed on surface of Philadelphia chromosome-positive acute lymphoblastic cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells. Leukemia 1999, 13:779-785.
5. Boccuni P., Di Noto R., Lo Pardo C., Villa M.R., Ferrara F., Rotoli B., et al. CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies. Tissue Antigens 1998, 52:1-8.
6. Kalina T., Vaskova M., Mejstrikova E., Madzo J., Trka J., Stary J., et al. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer 2005, 5:38.
7. Mori T., Sugita K., Suzuki T., Okazaki T., Manabe A., Hosoya R., et al. A novel monoclonal antibody, KOR- SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity. Leukemia 1995, 9:1233-1239.
8. Hrusák O., Trka J., Zuna J., Housková J., Bartůnková J., Starý J. Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity. The Pediatric Hematology Working Group in the Czech Republic. Leukemia 1998, 12:1064-1070.
9. Yamanka T., Kuroki M., Matsuo Y., Matsuoka Y. Analysis of heterophilic cell adhesion mediated by CD66b and CD66c using their soluble recombinant proteins. Biochem Biophys Res Commun 1996, 219:842-847.
10. Klein M.L., McGhee S.A., Baranian J., Stevens L., Hefta S.A. Role of non- specific cross-reacting antigen, a CD66 cluster antigen, in activation of human granulocytes. Infect Immun 1996, 64:4574-4579.
11. Kanderová V., Hrusák O., Kalina T. Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells. Exp Hematol 2010, 38:653-660.
12. Paulsson K., Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2009, 48:637-660.
13. Pui C.H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012, 120:1165-1174.
14. Harrison C.J., Moorman A.V., Broadfield Z.J., Cheung K.L., Harris R.L., Reza Jalali G., et al. Childhood and Adult Leukaemia Working Parties. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004, 125:552-559.
15. Nachman J.B., Heerema N.A., Sather H., Camitta B., Forestier E., Harrison C.J., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007, 110:1112-1115.
16. Greipp P.R., Trendle M.C., Leong T., Oken M.M., Kay N.E., Van Ness B., et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?. Leuk Lymphoma 1999, 35:83-89.
17. Baruchel A., Cayuela J.M., Ballerini P., Landman-Parker J., Cezard V., Firat H., et al. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol 1997, 99:101-106.
18. Behm F.G., Smith F.O., Raimondi S.C., Pui C.H., Bernstein I.D. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996, 87:1134-1139.
19. Uckun F.M. Regulation of human B-cell ontogeny. Blood 1990, 76:1908-1923.
20. Vaskova M., Fronkova E., Starkova J., Kalina T., Mejstrikova E., Hrusak O. CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis. Tissue Antigens 2008, 71:57-66.
21. Manabe A., Ohara A., Hasegawa D., Koh K., Saito T., Kiyokawa N., et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15. Haematologica 2008, 93:1155-1160.
22. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
23. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
24. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010, 107:252-257.
25. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
26. Cario G., Zimmermann M., Romey R., Gesk S., Vater I., Harbott J., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
27. Ensor H.M., Schwab C., Russell L.J., Richards S.M., Morrison H., Masic D., et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117:2129-2136.
28. Chen I.M., Harvey R.C., Mullighan C.G., Gastier-Foster J., Wharton W., Kang H., et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012, 119:3512-3522.
29. Palmi C., Vendramini E., Silvestri D., Longinotti G., Frison D., Cario G., et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012, 26:2245-2253.
30. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
31. Hunger S.P. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program 2011, 2011:361-365.
32. Andersson A., Olofsson T., Lindgren D., Nilsson B., Ritz C., Edén P., et al. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci USA 2005, 102:19069-19074.
33. Inazawa J., Abe T., Inoue K., Misawa S., Oikawa S., Nakazato H., et al. Regional assignment of nonspecific cross-reacting antigen (NCA) of the CEA gene family to chromosome 19 at band q13.2. Cytogenet Cell Genet 1989, 52:28-31.
34. Foà R., Vitale A., Vignetti M., Meloni G., Guarini A., De Propris M.S., et al. GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, 118:6521-6528.